Marker Therapeutics, Inc. (MRKR) — SEC Filings
Marker Therapeutics, Inc. (MRKR) — 38 SEC filings. Latest: 8-K (Nov 14, 2025). Includes 25 8-K, 6 10-Q, 3 DEF 14A.
View Marker Therapeutics, Inc. on SEC EDGAR
Overview
Marker Therapeutics, Inc. (MRKR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Marker Therapeutics, Inc. (MRKR) reported a net loss of $10,460,410 for the nine months ended September 30, 2025, a significant increase from the $6,893,691 net loss in the same period of 2024. This was primarily driven by a rise in research and development expenses to $9,658,322 in 2025 from $8,381
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bearish, 34 neutral, 2 mixed. The dominant filing sentiment for Marker Therapeutics, Inc. is neutral.
Filing Type Overview
Marker Therapeutics, Inc. (MRKR) has filed 25 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 1 8-K/A, 1 SC 13D/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of MRKR's 35 recent filings, 2 were flagged as high-risk, 22 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2,443,225 |
| Net Income | -$10,460,410 |
| EPS | -$0.75 |
| Debt-to-Equity | 0.18 |
| Cash Position | $18,942,953 |
| Operating Margin | -450.5% |
| Total Assets | $21,734,830 |
| Total Debt | $3,345,937 |
Key Executives
- Dr. Robert L. Ferris
- Dr. Juan F. Vera
- ALI BEHBAHANI
- ANTHONY A. FLORENCE, JR.
- CARMEN CHANG
- FOREST BASKETT
- MOHAMAD H. MAKHZOUMI
- PAUL WALKER
Industry Context
Marker Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cell therapies. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on securing substantial funding for clinical trials and navigating complex approval processes.
Top Tags
financials (8) · 8-K (5) · corporate-filing (4) · financial-reporting (4) · 10-Q (4) · material-agreement (4) · divestiture (4) · corporate-governance (3) · filing (3) · pharmaceutical (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $10.46M | Increased from $6.89M in prior year for nine months ended Sep 30, 2025 |
| Cash, Cash Equivalents, and Restricted Cash | $18.9M | As of September 30, 2025, down from $19.19M at Dec 31, 2024 |
| Net Proceeds from ATM Sales | $9.86M | From 5,358,292 common shares sold in July and August 2025 |
| Net Proceeds from Private Placement | $14.9M | Closed December 23, 2024 |
| Research and Development Expenses | $9.66M | For nine months ended Sep 30, 2025, up from $8.38M in prior year |
| Grant Income | $2.44M | For nine months ended Sep 30, 2025, down from $4.34M in prior year |
| Common Shares Outstanding | 16,673,127 | As of November 6, 2025, up from 10,709,005 at Jan 1, 2025 |
| Accumulated Deficit | $457.48M | As of September 30, 2025, indicating significant historical losses |
| Cash Runway | Q3 2026 | Anticipated period company can fund operations without additional capital |
| ATM Commission Rate | 3.0% | Paid to H.C. Wainwright & Co. LLC |
| Report Date | 20251031 | Date of earliest event reported |
| Fiscal Year End | 1231 | Company's fiscal year end |
| Commission File Number | 001-37939 | Identifier for the company's SEC filings |
| IRS Employer Identification No. | 45-4497941 | Tax identification number for the company |
| Total Revenues | $1.21M | Decreased by 49.8% for six months ended June 30, 2025, from $2.41M in 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Marker Therapeutics, Inc. (MRKR)?
Marker Therapeutics, Inc. has 38 recent SEC filings from Jan 2024 to Nov 2025, including 25 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MRKR filings?
Across 38 filings, the sentiment breakdown is: 2 bearish, 34 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Marker Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Marker Therapeutics, Inc. (MRKR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Marker Therapeutics, Inc.?
Key financial highlights from Marker Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MRKR?
The investment thesis for MRKR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Marker Therapeutics, Inc.?
Key executives identified across Marker Therapeutics, Inc.'s filings include Dr. Robert L. Ferris, Dr. Juan F. Vera, ALI BEHBAHANI, ANTHONY A. FLORENCE, JR., CARMEN CHANG and 3 others.
What are the main risk factors for Marker Therapeutics, Inc. stock?
Of MRKR's 35 assessed filings, 2 were flagged high-risk, 22 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Marker Therapeutics, Inc.?
Forward guidance and predictions for Marker Therapeutics, Inc. are extracted from SEC filings as they are enriched.